This observational study will assess the execution, efficacy and safety of treatment with MabThera in patients with rheumatoid arthritis. Data from patients receiving MabThera according to local treatment guidelines will be collected for 29 months. Target sample size is 100-200 patients.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01075477?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
